Contrast Agents and Radiopharmaceuticals – Market Insights – Europe

The COVID-19 pandemic negatively impacted the European contrast agents and radiopharmaceutical market in 2020. Following the recovery, growth in the European market will be supported by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by ASP erosion in some segments and the continued concern over gadolinium and radiation exposure in certain modalities along with stringent reimbursement regulations in the European market. 

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe from 2019 through 2032.

Contrast agents and radiopharmaceutical market will grow modestly over the forecast period.

Which segments will see the greatest growth through 2032, and what factors will drive this growth?

What factors are hampering growth of some segments?

Looming concerns over the effects of gadolinium retention will negatively affect the use of contrast-enhanced MRI.

How has the EMA responded to studies that call into question the safety of GBCAs?

Which companies (and associated products) will benefit from the shift to macrocyclic GBCAs?

To what extent will these studies impact the MRI contrast agent market through 2032?

Product innovation and the expansion of approved indications will support market growth.

What new products are anticipated to enter the European contrast agent and radiopharmaceutical market?

How will approval for new indications and surgeon adoption of these will impact market growth?